Latest Tax Refunds News

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Unith Ltd has strengthened its financial footing by securing a $1 million unsecured facility and receiving initial R&D tax refunds from Spain, validating its advanced AI platform and supporting its growth ambitions.

Pilot Energy has secured a $1.52 million financing facility to fast-track its FY2025 R&D Tax Incentive refund, supporting its clean energy and gas exploration projects.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Elixir Energy has raised approximately AUD 16.6 million through a two-tranche placement led by Omega Oil & Gas, aiming to fast-track its Taroom Trough gas projects and advance toward commercial production.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Elixir Energy has secured a specialized rig imported by Shell to drill the pivotal Lorelle-3 appraisal well in Queensland’s Taroom Trough, with operations set to begin in January 2026. This move aims to validate Elixir’s substantial gas resources adjacent to Shell’s acreage.